Listed

Sanofi: Form 20-F for the period ended Dec 31, 2019

Filed with the SEC on Mar 5, 2020 and accepted by EDGAR at Mar 5, 2020, 14:55 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Cost of revenue12 months2019-01-01 to 2019-12-31EUR 11.98bnifrs-full:CostOfSales
Gross profit12 months2019-01-01 to 2019-12-31EUR 25.66bnifrs-full:GrossProfit
Operating income12 months2019-01-01 to 2019-12-31EUR 3.13bnifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2019-01-01 to 2019-12-31EUR 139.0mifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2019-01-01 to 2019-12-31EUR 2.81bnifrs-full:ProfitLossAttributableToOwnersOfParent
Diluted EPS12 months2019-01-01 to 2019-12-31EUR 2.23ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2019-01-01 to 2019-12-31EUR 2.24ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2019-01-01 to 2019-12-31EUR 7.74bnifrs-full:CashFlowsFromUsedInOperatingActivities
Cash and equivalentsAt period end2019-12-31EUR 9.43bnifrs-full:CashAndCashEquivalents
Total assetsAt period end2019-12-31EUR 112.74bnifrs-full:Assets
Shareholders' equityAt period end2019-12-31EUR 58.93bnifrs-full:EquityAttributableToOwnersOfParent
Shares outstandingAt period end2019-12-311,253,826,630 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001121404-20-000006. Last ingested by Listed: Nov 5, 2026, 12:26 ET. Listed shows no prices and gives no investment advice.